CA2504280A1 - Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease - Google Patents

Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease Download PDF

Info

Publication number
CA2504280A1
CA2504280A1 CA002504280A CA2504280A CA2504280A1 CA 2504280 A1 CA2504280 A1 CA 2504280A1 CA 002504280 A CA002504280 A CA 002504280A CA 2504280 A CA2504280 A CA 2504280A CA 2504280 A1 CA2504280 A1 CA 2504280A1
Authority
CA
Canada
Prior art keywords
epa
dha
content
mixture
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504280A
Other languages
French (fr)
Inventor
Cees-Nico Verboom
Rainer Oelze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of CA2504280A1 publication Critical patent/CA2504280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention concerns the use of a pharmaceutical composition containing essential fatty acid ethyl esters originating from fish oils, in particular as a high concentration mixture of ethyl esters of (20:5.omega. 3) eicosapentaenoic acid (EPA) and (22:6.omega. 3) docosahexaenoic acid (DHA) in the prevention and/or treatment of depression in patients with cardiovascular disease, such as coronary heart and/or coronary artery or vascular disease.

Claims (32)

1. A method for preventing and/or treating depression in patients with cardiovascular disease comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a high content in eicosapentanoic acid ethyl ester (EPA), in docosahexaenoic acid ethyl ester (DHA) or in a high concentration mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA).
2. The method of claim 1 wherein the cardiovascular disease is coronary heart and/or coronary artery or vascular disease.
3. The method of claim 2 wherein the cardiovascular disease is coronary artery or vascular disease.
4. The method of any one of claims 1-3 wherein the essential fatty acids contain a high concentration mixture of EPA and DHA.
5. The method of any one of claims 1-3 wherein the essential fatty acids contain a high content in EPA or in DHA.
6. The method of claim 4 wherein the content in EPA and DHA in such mixture is at least 20% b.w.
7. The method of claim 4 wherein the content in EPA and DHA in such mixture is at least 25% b.w.
8. A method according to claim 4, wherein the content in EPA and DHA in such mixture is from about 30 to about 100% b.w.
9. A method according to claim 4 wherein the content in EPA and DHA in such mixture is from about 30 to about 85% b.w.
10. A method according to any one of claims 4, 6-9, wherein the medicament is administered orally.
11. A method according to claim 10, wherein the medicament is administered orally at a dosage from about 0.7 g to about 6 g daily.
12. A method according to claim 11, wherein the EPA/DHA ratio by weight in the EPA and DHA mixture is about 0.9 to 1.5.
13. The method of claim 5 wherein the content in EPA or DHA is at least 20%
b.w.
14. The method of claim 5 wherein the content in EPA or DHA is at least 25%
b.w.
15. The method of claim 5 wherein the content in EPA or DHA is from about 60-100% b.w.
16. The method of any one of claims 5, 13-15 wherein the content in EPA or DHA
is administered orally.
17. A use of a therapeutically effective amount of a medicament containing a high content in EPA, in DHA or in a high concentration mixture of EPA and DHA and a pharmaceutically acceptable vehicle for the treatment of depression in patients with cardiovascular disease.
18. The use of claim 17 wherein the cardiovascular disease is coronary heart and/or coronary artery or vascular disease.
19. The use of claim 18 wherein the cardiovascular disease is coronary artery or vascular disease.
20. The use of any one of claims 17-19 wherein the essential fatty acids contain a high concentration mixture of EPA and DHA.
21. The use of any one of claims 17-19 wherein the essential fatty acids contain a high content in EPA or in DHA.
22. The use of claim 20 wherein the content in EPA and DHA in such mixture is at least 20%
b.w.
23. The use of claim 20 wherein the content in EPA and DHA in such mixture is at least 25%
b.w.
24. A use according to claim 20, wherein the content in EPA and DHA in such mixture is from about 30 to about 100% b.w.
25. A use according to claim 20 wherein the content in EPA and DHA in such mixture is from about 30 to about 85% b.w.
26. A use according to any one of claims 20, 22-25, wherein the medicament is administered orally.
27. A use according to claim 26, wherein the medicament is administered orally at a dosage from about 0.7 g to about 6 g daily.
28. A use according to claim 27, wherein the EPA/DHA ratio by weight in the EPA and DHA
mixture is about 0.9 to 1.5.
29. The use of claim 21 wherein the content in EPA or DHA is at least 20% b.w.
30. The use of claim 21 wherein the content in EPA or DHA is at least 25% b.w.
31. The use of claim 21 wherein the content in EPA or DHA is from about 60-100% b.w.
32. The use of any one of claims 21, 29-31 wherein the content in EPA or DHA
is administered orally.
CA002504280A 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease Abandoned CA2504280A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101578 2004-04-16
EPEP04101578.5 2004-04-16

Publications (1)

Publication Number Publication Date
CA2504280A1 true CA2504280A1 (en) 2005-10-16

Family

ID=34928968

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504280A Abandoned CA2504280A1 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Country Status (12)

Country Link
EP (1) EP1765319A1 (en)
JP (1) JP2007532605A (en)
CN (1) CN1942180A (en)
AU (1) AU2005244483B2 (en)
BR (1) BRPI0509878A (en)
CA (1) CA2504280A1 (en)
IL (1) IL178300A0 (en)
MX (1) MX291518B (en)
RU (1) RU2387448C2 (en)
UA (1) UA94693C2 (en)
WO (1) WO2005110393A1 (en)
ZA (1) ZA200607794B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
ITMI20100961A1 (en) * 2010-05-27 2011-11-28 Erredue Spa MIXTURES RICH IN OMEGA-3 FATTY ACIDS, THEIR COMPOSITIONS AND THEIR PREPARATION PROCESS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
WO2002096408A1 (en) * 2001-05-30 2002-12-05 Laxdale Limited Coenzyme q and eicosapentaenoic acid (epa)

Also Published As

Publication number Publication date
WO2005110393A1 (en) 2005-11-24
AU2005244483B2 (en) 2011-06-09
AU2005244483A1 (en) 2005-11-24
IL178300A0 (en) 2007-02-11
ZA200607794B (en) 2008-05-28
MX291518B (en) 2011-10-31
MXPA06011940A (en) 2006-12-15
EP1765319A1 (en) 2007-03-28
BRPI0509878A (en) 2007-10-16
JP2007532605A (en) 2007-11-15
CN1942180A (en) 2007-04-04
RU2387448C2 (en) 2010-04-27
RU2006140277A (en) 2008-05-27
UA94693C2 (en) 2011-06-10

Similar Documents

Publication Publication Date Title
CN1198608C (en) Therapeutic and dietary compsns. containing essential fatty acids and bioactive disulphides
KR100657642B1 (en) Oil comprising eicosapentaenoic acid and/or stearidonic acid
CA1261274A (en) Pharmaceutical and dietary compositions
KR101336756B1 (en) Composition for prevention of recurrence of stroke
JP2020128412A5 (en)
KR20070098954A (en) A pharmaceutical composition containing essential fatty acids in the prevention of cardiovascular events
JP2006519244A (en) Use of omega-3-fatty acids in the treatment of diabetic patients
WO2010038796A1 (en) Therapeutic agent for hepatitis c
KR20040004652A (en) Coenzyme q and eicosapentaenoic acid (epa)
NZ248422A (en) Use of(dihomo-)gamma-linolenic acid (dgla,gla) or linoleic acid(la) to increase gut calcium absorption in humans
JPH0232017A (en) Essential fatty acid composition and it production
WO2009091538A8 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
WO2012112531A1 (en) Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
EP0517425A1 (en) Fatty acids for the reduction of urinary calcium excretion and the treatment of osteoporosis
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
CN1126564C (en) Use of phospholipid complexes of extracts of i(vitis vinifera) as anti-atherosclerotic agent
IE54558B1 (en) Pharmaceutical composition
EP0257081A1 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
CA2504280A1 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
WO2014095628A1 (en) Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)
MX2011001419A (en) Long-term treatment of symptomatic heart failure.
Eritsland et al. Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile
JPH0399011A (en) Pharmaceutical composition
EP2675442A1 (en) Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
JP5952556B2 (en) Pressure ulcer treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141014

FZDE Discontinued

Effective date: 20141014